Publications by authors named "M Espuna Pons"

Background And Aims: Around 750,000 patients per year will be cured of HCV infection until 2030. Those with compensated advanced chronic liver disease remain at risk for hepatic decompensation and de novo HCC. Algorithms have been developed to stratify risk early after cure; however, data on long-term outcomes and the prognostic utility of these risk stratification algorithms at later time points are lacking.

View Article and Find Full Text PDF

Purpose: Studies evaluating the long-term survival rate, patient satisfaction, and conversion to total hip arthroplasty (THA) are limited. The aim of this study was to evaluate satisfaction and hip survival at a minimum 10-year follow-up in patients following hip arthroscopy for femoroacetabular impingement syndrome (FAIS).

Methods: A total of 164 patients underwent hip arthroscopy for FAIS between 2007 and 2012; of these, 76 (49 men and 27 women; mean age, 40.

View Article and Find Full Text PDF

Unconsidered microorganisms, such as may be often recovered from food samples. This study aimed to characterize seven recovered from traditional market chicken meat in Lima, Peru. Antimicrobial susceptibility to 18 antimicrobial agents as well as the presence of amino acid changes in fluoroquinolone targets, 10 mediated colistin resistance () genes and integrons were analyzed.

View Article and Find Full Text PDF
Article Synopsis
  • Orogenic growth leads to crustal thickening, which increases elevation and enhances precipitation, thus impacting erosion and deformation processes.
  • A numerical model shows that rock uplift, precipitation, and erosion rates in intermediate erodibility orogens are highly correlated, particularly during the formation of orogenic plateaus.
  • The study reveals how the development of new faults affects the cyclical relationships among these processes, offering insights into erosion controls in active mountain ranges like the Himalayas and potentially resolving conflicting interpretations related to fault maturity.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the retention rates and remission outcomes of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who started treatment with secukinumab over 24 and 48 months.
  • Data was collected from 13 European registries, revealing that retention rates were around 51%-64%, and patients with no prior biologic treatments showed better outcomes compared to those with previous treatments.
  • The findings suggest that secukinumab remains effective over four years, with higher success rates in treatment-naïve patients compared to those who had already tried other therapies.
View Article and Find Full Text PDF